Dynamic changes and clinical significance of serum tryptase levels in STEMI patients treated with primary PCI

• Published in: Biomarkers Vol. 19; no. 7; pp. 620 - 624
• Main Authors: Chen, Shaomin, Mu, Di, Cui, Ming, Ren, Chuan, Zhang, Shu, Guo, Lijun, Gao, Wei
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.11.2014; Taylor & Francis
• Subjects: Acute myocardial infarction; Aged; Biomarkers - blood; Case-Control Studies; Female; Humans; Male; mast cell; Middle Aged; Myocardial Contraction; Myocardial Infarction - blood; Myocardial Infarction - diagnosis; Myocardial Infarction - enzymology; Myocardial Infarction - physiopathology; Myocardial Infarction - therapy; Percutaneous Coronary Intervention - adverse effects; Recovery of Function; ST-segment resolution; Stroke Volume; Time Factors; Treatment Outcome; tryptase; Tryptases - blood; Ventricular Function, Left; mast cell; Acute myocardial infarction; tryptase; ST-segment resolution
• ISSN: 1354-750X; 1366-5804; 1366-5804
• DOI: 10.3109/1354750X.2014.960452

Abstract Objective: To investigate the dynamic changes in serum tryptase levels and their association with clinical data in patients with acute ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Methods: Serum tryptase levels were measured in 99 STEMI patients and 25 control subjects. Results: Tryptase levels were significantly increased at admission, and descended after primary PCI. Tryptase levels at 0.5, 2 and 6 h after PCI were negatively correlated with the percentage of ST-segment resolution (STR) as well as left ventricular ejection fraction (LVEF). Conclusions: High tryptase levels after PCI were associated with poor myocardial reperfusion and poor cardiac function.